Main Conference Takeaways Regarding cGVHD Management

January 13, 2025

Sergio A. Giralt, MD

Opinion

Video

Sergio A. Giralt, MD, discusses the key results from recent chronic graft-vs-host disease (cGVHD) research presented at ASH 2024 and how these findings will influence his clinical practice. He also shares his main takeaways on evolving strategies for cGVHD management.

EP: 1.The Pathophysiology of Chronic Graft-Vs -Host Disease (cGVHD) and the Role of CSF1R

EP: 2.Examining Axatilimab in the AGAVE-201 Trial For cGVHD

EP: 3.Exploring Combination Therapy with Ibrutinib and Rituximab in cGVHD

EP: 4.Discussing Real-World Ruxolitinib and Corticosteroid Treatment Patterns in Patients with cGVHD

EP: 5.The Role of Posttransplant Cyclophosphamide in Patients With cGVHD

Now Viewing

EP: 6.Main Conference Takeaways Regarding cGVHD Management

Video content above is prompted by the following:

What were the key results seen in this abstract and will they carry over to your clinical practice?
What were your main takeaways with regard to chronic graft-vs-host disease management from ASH 2024?

Related Content

ICYMI: Highlights From AMCP Nexus 2024

December 26th 2024

Article

Check out this year's top coverage from The Academy of Managed Care Pharmacy (AMCP) Nexus 2024 meeting, which included relevant topics in health care policy, novel pharmaceutical developments, financial considerations across multiple conditions, and more.

ICYMI: Highlights From ASCO 2024

December 21st 2024

Article

Top coverage from the 2024 American Society of Clinical Oncology (ASCO) annual meeting included research topics in non-small cell lung cancer (NSCLC), multiple myeloma, metastatic colorectal cancer (mCRC), and more.

ICYMI: Highlights From SLEEP 2024

December 18th 2024

Article

Check out our top 5 most-viewed pieces of coverage from the 2024 SLEEP meeting.

ICYMI: Highlights From ACTRIMS 2024

December 12th 2024

Article

Read about the diverse array of research presented at this year's meeting, including novel technological advancements and insights into disease progression in multiple sclerosis (MS).